Matching articles for "sacituzumab govitecan"
Issue 1671 · March 6, 2023 Free
In Brief: A New Breast Cancer Indication for Sacituzumab Govitecan (Trodelvy) (online only)

Sacituzumab govitecan-hziy ( Trodelvy – Gilead) has been approved for treatment of unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2…

Med Lett Drugs Ther. 2023 Mar 6; 65(1671):e43-4 doi:10.58347/tml.2023.1671g
Sacituzumab govitecan-hziy ( Trodelvy – Gilead) has been approved for treatment of unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer in adults who received prior endocrine therapy and ≥2 additional systemic therapies for metastatic disease. It was previously approved for treatment-refractory metastatic triplenegative breast cancer and for treatment of locally advanced or metastatic urothelial cancer in adults who received platinum-based chemotherapy and a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
Issue 1617 · February 8, 2021
Sacituzumab Govitecan (Trodelvy) for Metastatic Triple-Negative Breast Cancer (online only)

The FDA has approved sacituzumab govitecan-hziy ( Trodelvy – Immunomedics), a trophoblast cell-surface antigen-2 (Trop-2)-directed antibody and topoisomerase inhibitor conjugate, for treatment of adults with…

Med Lett Drugs Ther. 2021 Feb 8; 63(1617):e24-5
The FDA has approved sacituzumab govitecan-hziy ( Trodelvy – Immunomedics), a trophoblast cell-surface antigen-2 (Trop-2)-directed antibody and topoisomerase inhibitor conjugate, for treatment of adults with metastatic triple-negative breast cancer who have received ≥2 prior therapies for metastatic disease. It is the first Trop-2-directed antibody-drug conjugate to become available in the US.